Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 4, 2006

Neurobiological Technologies and Nordmark Complete GMP Snake Facility

  • Neurobiological Technologies (NTI) completed construction of a snake facility in Moorrege, Germany, near Hamburg. The facility, owned and operated by NTI’s partner, Nordmark Arzneimittel, houses snakes that will provide the venom used to produce Viprinex, which is being studied by NTI as a potential treatment for acute ischemic stroke.

    “A home was needed for the snakes used to produce Viprinex, and we decided with Nordmark that it was necessary to create one of the world’s few GMP facilities for reptiles,” says Paul E. Freiman, CEO of NTI. “This facility currently houses 100 snakes and is expected to eventually be home to 1,500 vipers.”

    According to Freiman, the two companies shared the expense of this facility at a cost of EUR4.5 million.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »